Genome patent overturned

Yesterday the British High Court overturned a UK genome patent owned by biotech Human Genome Sciences. The patent covered the inflammation-linked protein neutrokine-alpha which is part of the tumor necrosis factor family of cytokines. The court overturned the patent, ruling that at the time its application was filed there was no practical application, the Financial Times linkurl:reported.;http://www.ft.com/cms/s/0/c2649894-5f54-11dd-91c0-000077b07658.html?nclick_check=1 Human Genome Science

By | August 1, 2008

Yesterday the British High Court overturned a UK genome patent owned by biotech Human Genome Sciences. The patent covered the inflammation-linked protein neutrokine-alpha which is part of the tumor necrosis factor family of cytokines. The court overturned the patent, ruling that at the time its application was filed there was no practical application, the Financial Times linkurl:reported.;http://www.ft.com/cms/s/0/c2649894-5f54-11dd-91c0-000077b07658.html?nclick_check=1 Human Genome Sciences applied for the patent in the mid-1990s. But the ruling might really affect Eli Lilly, who has spent $50 million developing an antibody to neutrokine-alpha and is looking to spend another $250 million bringing the therapy through clinical trials, the Times reported.

Popular Now

  1. What Budget Cuts Might Mean for US Science
    News Analysis What Budget Cuts Might Mean for US Science

    A look at the historical effects of downsized research funding suggests that the Trump administration’s proposed budget could hit early-career scientists the hardest.  

  2. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  3. Opinion: On “The Impact Factor Fallacy”
  4. Unstructured Proteins Help Tardigrades Survive Desiccation
Business Birmingham